Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The financing will
Share this article
Share this article
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ Notch Therapeutics Inc., a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond, Ph.D. as Senior Vice President, Preclinical and Translational Sciences. Dr. Bond joins Notch from Kite, where he most recently served as Vice President of Cellular Engineering. We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND, said David Main, President and Chief Executive Officer of Notch. Adding Chris to our leadership team will bolster our preclinical pipeline and translational research capabilities to accelerate development of the company s cell therapy candidates from discovery into clinical application.
Inhibikase Therapeutics Announces Closing of Initial Public Offering
News provided by
Share this article
Share this article
ATLANTA, Dec. 28, 2020 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase ), a clinical-stage pharmaceutical company developing therapeutics for Parkinson s disease and related disorders that arise inside and outside of the brain, announced today the closing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase, were $18 million. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of Inhibikase s common stock at the initial public offering price, less underwriting discounts and commissions.
Share this article
Share this article
ATLANTA, Dec. 22, 2020 /PRNewswire/ Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson s disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share, for gross proceeds of $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase. All of the shares are being offered by Inhibikase. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.